Stock ACAD ACADIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/06/2024 BST 		5-day change 1st Jan Change
15.3 USD +3.73% Intraday chart for ACADIA Pharmaceuticals Inc. +2.62% -51.13%
05-16 Transcript : ACADIA Pharmaceuticals Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM
05-14 Transcript : ACADIA Pharmaceuticals Inc. Presents at The Citizens JMP Life Sciences Conference, May-14-2024 01:30 PM

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,589 8,499 3,752 2,578 5,140 2,528 - -
Enterprise Value (EV) 1 5,892 7,867 3,231 2,161 4,702 1,958 1,742 1,372
P/E ratio -26.7 x -29.9 x -22.2 x -11.9 x -84.6 x 26.7 x 13.4 x 9.43 x
Yield - - - - - - - -
Capitalization / Revenue 19.4 x 19.2 x 7.75 x 4.98 x 7.08 x 2.65 x 2.36 x 2.09 x
EV / Revenue 17.4 x 17.8 x 6.67 x 4.18 x 6.47 x 2.05 x 1.63 x 1.14 x
EV / EBITDA -24.2 x -27.7 x -19.3 x -9.75 x -69.3 x 23.6 x 8.92 x 4.15 x
EV / FCF -38.7 x -54.7 x -25.5 x -19 x 282 x 21.7 x 7.09 x 4.01 x
FCF Yield -2.58% -1.83% -3.92% -5.28% 0.35% 4.62% 14.1% 24.9%
Price to Book 9.5 x 13.6 x 6.95 x 6.44 x 11.9 x 4.29 x 2.9 x 2.09 x
Nbr of stocks (in thousands) 154,025 158,978 160,756 161,931 164,180 165,221 - -
Reference price 2 42.78 53.46 23.34 15.92 31.31 15.30 15.30 15.30
Announcement Date 26/02/20 24/02/21 28/02/22 27/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 339.1 441.8 484.1 517.2 726.4 953.9 1,069 1,207
EBITDA 1 -243.8 -283.7 -167.1 -221.6 -67.83 83.13 195.2 330.2
EBIT 1 -246.5 -286.6 -170.4 -223.6 -73.38 90.11 182.2 303.2
Operating Margin -72.71% -64.87% -35.2% -43.23% -10.1% 9.45% 17.04% 25.12%
Earnings before Tax (EBT) 1 -234.4 -281 -167.5 -213.4 -51.04 106.4 208.3 334.4
Net income 1 -235.3 -281.6 -167.9 -216 -61.29 101 212.9 314.6
Net margin -69.38% -63.74% -34.67% -41.76% -8.44% 10.59% 19.91% 26.06%
EPS 2 -1.600 -1.790 -1.050 -1.340 -0.3700 0.5738 1.140 1.622
Free Cash Flow 1 -152.3 -143.8 -126.8 -114 16.65 90.4 245.8 341.9
FCF margin -44.9% -32.54% -26.19% -22.05% 2.29% 9.48% 22.99% 28.33%
FCF Conversion (EBITDA) - - - - - 108.74% 125.94% 103.56%
FCF Conversion (Net income) - - - - - 89.53% 115.48% 108.68%
Dividend per Share 2 - - - - - - - -
Announcement Date 26/02/20 24/02/21 28/02/22 27/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 130.8 115.5 134.6 130.7 136.5 118.5 165.2 211.7 231 205.8 235.6 249.8 261.4 242.3 270.2
EBITDA 1 -44.12 -112.1 -33.04 -30.36 -45.57 -53.16 4.803 -56.05 36.58 15.45 34.92 31.77 10.81 - -
EBIT 1 -44.66 -113 -33.65 -30.87 -46.06 -53.58 3.037 -57.78 34.94 15.21 30.39 29.19 18.04 13.78 41.67
Operating Margin -34.15% -97.88% -25.01% -23.61% -33.75% -45.23% 1.84% -27.29% 15.12% 7.39% 12.9% 11.68% 6.9% 5.69% 15.42%
Earnings before Tax (EBT) 1 -42.9 -112.6 -33.57 -26.42 -40.89 -44.94 6.343 -52.14 39.7 21 34.8 30.25 22.36 27.01 45.2
Net income 1 -43.09 -113.1 -34.01 -27.18 -41.72 -43.02 1.114 -65.18 45.8 16.56 32.43 28.98 22.15 25.88 43.31
Net margin -32.96% -97.91% -25.28% -20.8% -30.57% -36.32% 0.67% -30.79% 19.82% 8.04% 13.77% 11.6% 8.47% 10.68% 16.02%
EPS 2 -0.2700 -0.7000 -0.2100 -0.1700 -0.2600 -0.2700 0.0100 -0.4000 0.2800 0.1000 0.1856 0.1707 0.1223 0.1300 0.2200
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 28/02/22 04/05/22 08/08/22 02/11/22 27/02/23 08/05/23 02/08/23 02/11/23 27/02/24 08/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 697 632 521 417 439 570 786 1,156
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -152 -144 -127 -114 16.7 90.4 246 342
ROE (net income / shareholders' equity) -39.9% -42.5% -28.7% -45.9% -14.7% 18% 30% 26.2%
ROA (Net income/ Total Assets) -35.6% -36% -22.6% -33.5% -9.17% 12.6% 26.6% 16.6%
Assets 1 661.7 782.9 741.4 644 668.4 798.7 800.2 1,901
Book Value Per Share 2 4.500 3.930 3.360 2.470 2.640 3.560 5.280 7.310
Cash Flow per Share 2 -1.030 -0.8700 -0.7800 -0.7100 0.1000 1.000 1.200 3.240
Capex 1 1.13 7.59 1.12 - 0.05 3.69 2.71 1.82
Capex / Sales 0.33% 1.72% 0.23% - 0.01% 0.39% 0.25% 0.15%
Announcement Date 26/02/20 24/02/21 28/02/22 27/02/23 27/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ACADIA Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
15.3 USD
Average target price
27.16 USD
Spread / Average Target
+77.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ACADIA PHARMACEUTICALS INC. Stock ACADIA Pharmaceuticals Inc.
-51.13% 2.53B
MODERNA, INC. Stock Moderna, Inc.
+34.14% 51.12B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.54% 39.4B
LONZA GROUP AG Stock Lonza Group AG
+34.92% 38.48B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.62% 26.36B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-13.43% 20.96B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+43.73% 14.02B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.81% 12.49B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.54% 11.61B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACAD Stock
  4. Financials ACADIA Pharmaceuticals Inc.